ID   COLO 206F
AC   CVCL_1988
SY   Colo-206F; COLO-206F; Colo 206F; COLO206F; COLO 206; COLO206; Colorado 206F
DR   BTO; BTO:0002199
DR   CLO; CLO_0002570
DR   EFO; EFO_0006554
DR   CLDB; cl864
DR   ArrayExpress; E-MTAB-2706
DR   cancercelllines; CVCL_1988
DR   Cell_Model_Passport; SIDM00822
DR   ColonAtlas; COLO206F
DR   Cosmic; 2760082
DR   DSMZ; ACC-21
DR   DSMZCellDive; ACC-21
DR   ECACC; 93052620
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM206460
DR   GEO; GSM274776
DR   GEO; GSM513935
DR   GEO; GSM514188
DR   GEO; GSM784009
DR   GEO; GSM1374453
DR   LINCS_LDP; LCL-1159
DR   PharmacoDB; COLO206F_215_2019
DR   Progenetix; CVCL_1988
DR   Wikidata; Q54814077
RX   PubMed=6277475;
RX   PubMed=8464898;
RX   PubMed=10051639;
RX   PubMed=11668190;
RX   PubMed=20606684;
RX   PubMed=23272949;
RX   PubMed=25485619;
RX   PubMed=26589293;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: AstraZeneca Colorectal cell line (AZCL) panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: ~2-3 days (DSMZ=ACC-21).
CC   HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01,07:01 (PubMed=26589293).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 10,12
ST   D16S539: 12,13
ST   D18S51: 18
ST   D19S433: 13,14
ST   D21S11: 30.2,33.2
ST   D2S1338: 17,18
ST   D3S1358: 16
ST   D5S818: 10,13
ST   D7S820: 9,10
ST   D8S1179: 9,14
ST   FGA: 21,23
ST   Penta D: 9,11
ST   Penta E: 13,15
ST   TH01: 8,9
ST   TPOX: 11
ST   vWA: 15
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_9976 ! COLO 197
OI   CVCL_9977 ! COLO 200
OI   CVCL_1987 ! COLO 201
OI   CVCL_0218 ! COLO 205
SX   Male
AG   70Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   PubMed=6277475;
RA   Frampton R.J., Suva L.J., Eisman J.A., Findlay D.M., Moore G.E.,
RA   Moseley J.M., Martin T.J.;
RT   "Presence of 1,25-dihydroxyvitamin D3 receptors in established human
RT   cancer cell lines in culture.";
RL   Cancer Res. 42:1116-1119(1982).
//
RX   PubMed=8464898; DOI=10.1073/pnas.90.7.2842;
RA   Browning M.J., Krausa P., Rowan A.J., Bicknell D.C., Bodmer J.G.,
RA   Bodmer W.F.;
RT   "Tissue typing the HLA-A locus from genomic DNA by sequence-specific
RT   PCR: comparison of HLA genotype and surface expression on colorectal
RT   tumor cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993).
//
RX   PubMed=10051639; DOI=10.1073/pnas.96.5.2316;
RA   Efstathiou J.A., Liu D., Wheeler J.M., Kim H.C., Beck N.E., Ilyas M.,
RA   Karayiannakis A.J., Mortensen N.J., Kmiot W., Playford R.J.,
RA   Pignatelli M., Bodmer W.F.;
RT   "Mutated epithelial cadherin is associated with increased
RT   tumorigenicity and loss of adhesion and of responsiveness to the
RT   motogenic trefoil factor 2 in colon carcinoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2316-2321(1999).
//
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=23272949; DOI=10.1186/1755-8794-5-66;
RA   Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A.,
RA   Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A.,
RA   Orphanides G., French T., Wessels L.F.A.;
RT   "Subtypes of primary colorectal tumors correlate with response to
RT   targeted treatment in colorectal cell lines.";
RL   BMC Med. Genomics 5:66.1-66.15(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//